The University of Southampton

Bioinvent International Ab

Biovent International Ab

Björn Frendéus

Ingrid Teige

Linda Mårtensson

Mark Steven Cragg

Monika Semmrich

Ali Roghanian

Stephen Beers

Petra Holmkvist

Robert Oldham

Jenny Mattsson

Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-α binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in treatment of cancer or infections caused by intracellular pathogens.

Antagonistic anti-TNFR2 antibodies

Described is the use of a first antibody molecule that specifically binds FcγRIIb via its Fab region, but lacks Fc region or has reduced binding to Fcγ receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an FcγRIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Combination and use of antibodies

Growing community of inventors

Lund, Sweden

Björn Frendéus